SG11202009147UA - Vaccine compositions - Google Patents

Vaccine compositions

Info

Publication number
SG11202009147UA
SG11202009147UA SG11202009147UA SG11202009147UA SG11202009147UA SG 11202009147U A SG11202009147U A SG 11202009147UA SG 11202009147U A SG11202009147U A SG 11202009147UA SG 11202009147U A SG11202009147U A SG 11202009147UA SG 11202009147U A SG11202009147U A SG 11202009147UA
Authority
SG
Singapore
Prior art keywords
vaccine compositions
vaccine
compositions
Prior art date
Application number
SG11202009147UA
Other languages
English (en)
Inventor
Laurens Rademacher
Thomas Rademacher
Ramila Philip
Original Assignee
Emergex Vaccines Holding Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergex Vaccines Holding Ltd filed Critical Emergex Vaccines Holding Ltd
Publication of SG11202009147UA publication Critical patent/SG11202009147UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SG11202009147UA 2018-03-29 2019-03-29 Vaccine compositions SG11202009147UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862649804P 2018-03-29 2018-03-29
PCT/GB2019/050928 WO2019186199A1 (fr) 2018-03-29 2019-03-29 Compositions vaccinales

Publications (1)

Publication Number Publication Date
SG11202009147UA true SG11202009147UA (en) 2020-10-29

Family

ID=66240161

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009147UA SG11202009147UA (en) 2018-03-29 2019-03-29 Vaccine compositions

Country Status (9)

Country Link
US (1) US20210093708A1 (fr)
EP (1) EP3773705A1 (fr)
JP (1) JP2021519762A (fr)
CN (1) CN112292148A (fr)
AU (1) AU2019244435A1 (fr)
BR (1) BR112020019719A2 (fr)
PH (1) PH12020551535A1 (fr)
SG (1) SG11202009147UA (fr)
WO (1) WO2019186199A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111615397A (zh) 2017-11-03 2020-09-01 武田疫苗股份有限公司 寨卡疫苗和免疫原性组合物及其使用方法
CN111601885A (zh) 2017-11-30 2020-08-28 武田疫苗股份有限公司 用于将寨卡病毒灭活的方法和相关方法
JP2024507808A (ja) 2021-02-16 2024-02-21 エマージェクス ヴァクシーンズ ホールディング リミテッド 逆ペプチド

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0025414D0 (en) 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
JP5117191B2 (ja) * 2004-10-01 2013-01-09 ミダテック リミテッド 抗原及びアジュバントを含むナノ粒子、並びに免疫原性構造
WO2007015105A2 (fr) 2005-08-04 2007-02-08 Thomas William Rademacher Nanoparticules comprenant des ligands antibacteriens
ES2369608T3 (es) 2006-04-13 2011-12-02 Midatech Ltd. Nanopartículas que contienen tres ligandos diferentes para proporcionar respuestas inmunitarias frente a agentes infecciosos.
US9598479B2 (en) 2011-09-07 2017-03-21 Midatech Ltd. Nanoparticle-peptide compositions
US10117922B2 (en) * 2014-05-13 2018-11-06 Emergex Vaccines Holding Ltd. Dengue virus specific multiple HLA binding T cell epitopes for the use of universal vaccine development
CN108601825B (zh) * 2015-07-16 2023-06-20 巴拉特生物技术国际有限公司 疫苗组合物
WO2017140905A1 (fr) * 2016-02-17 2017-08-24 Curevac Ag Vaccin contre le virus zika
SG11202002044WA (en) * 2017-09-21 2020-04-29 Emergex Vaccines Holding Ltd MHC Class I Associated Peptides for Prevention and Treatment of Zika Virus
SG11202005772YA (en) * 2018-01-06 2020-07-29 Emergex Vaccines Holding Ltd Mhc class i associated peptides for prevention and treatment of multiple flavi virus

Also Published As

Publication number Publication date
JP2021519762A (ja) 2021-08-12
WO2019186199A1 (fr) 2019-10-03
PH12020551535A1 (en) 2021-06-07
AU2019244435A1 (en) 2020-10-15
BR112020019719A2 (pt) 2021-01-26
CN112292148A (zh) 2021-01-29
US20210093708A1 (en) 2021-04-01
EP3773705A1 (fr) 2021-02-17

Similar Documents

Publication Publication Date Title
ZA201801035B (en) Vaccine compositions
GB201811312D0 (en) Compositions
GB2586745B (en) Compositions
SG11202010821TA (en) Vaccine composition
SG11202009259VA (en) Compositions
GB201802339D0 (en) Immunogenic composition
SG11202104306XA (en) Compositions
SG11202009147UA (en) Vaccine compositions
GB201910794D0 (en) Vaccine
IL282753A (en) Immunogenic compounds
GB201803923D0 (en) Compositions
GB2562241B (en) Vaccine compositions
IL271603A (en) Immunogenic preparations
GB201703529D0 (en) Vaccine composition
EP3710051A4 (fr) Compositions de vaccin
GB201819206D0 (en) Novel compositions
GB2570649B (en) Compositions
GB201811382D0 (en) Vaccine
GB201805676D0 (en) Compositions
GB201803692D0 (en) Immunogenic composition
GB201809541D0 (en) Vaccine compositions
GB201805393D0 (en) Vaccine compositions
GB201906072D0 (en) Vaccine compositions
GB201807376D0 (en) HMCV Vaccine Composition
GB201807378D0 (en) Vaccine composition